Division of Pulmonary, Allergy and Critical Care, Duke University Medical Center, Durham, North Carolina.
Division of Pulmonary, Allergy and Critical Care, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Durham, North Carolina.
J Heart Lung Transplant. 2020 Oct;39(10):1089-1099. doi: 10.1016/j.healun.2020.06.010. Epub 2020 Jun 20.
Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication following lung transplant. We studied incidence and risk factors for PTLD in adult lung transplant recipients (LTRs) using the International Society for Heart and Lung Transplantation Registry.
The International Society for Heart and Lung Transplantation Registry was used to identify adult, first-time, single and bilateral LTRs with at least 1 year of follow-up between 2006 and 2016. Kaplan-Meier method was used to describe the timing and distribution of PTLD. Univariable and multivariable Cox proportional hazards regression models were used to examine clinical characteristics associated with PTLD.
Of 19,309 LTRs in the analysis cohort, we identified 454 cases of PTLD. Cumulative incidence of PTLD was 1.1% (95% CI = 1.0%-1.3%) at 1 year and 4.1% (95% CI = 3.6%-4.6%) at 10 years. Of the PTLD cases, 47.4% occurred within the first year following lung transplantation. In the multivariable model, independent risk factors for PTLD included age, Epstein-Barr virus serostatus, restrictive lung diseases, and induction. Risk of PTLD during the first year after transplant increased with increasing age in patients between 45 and 62 years at time of transplantation; the inverse was true for ages <45 years or >62 years. Finally, receiving a donor organ with human leukocyte antigen types A1 and A24 was associated with an increased risk of PTLD, whereas the recipient human leukocyte antigen type DR11 was associated with a decreased risk.
Our study indicates that PTLD is a relatively rare complication among adult LTRs. We identified clinical characteristics that are associated with an increased risk of PTLD.
移植后淋巴组织增生性疾病(PTLD)是肺移植后的一种危及生命的并发症。我们使用国际心肺移植协会登记处研究了成人肺移植受者(LTR)中 PTLD 的发生率和危险因素。
使用国际心肺移植协会登记处确定了 2006 年至 2016 年间至少有 1 年随访的成人、首次、单肺和双肺 LTR,且为单侧移植。Kaplan-Meier 法用于描述 PTLD 的时间和分布。单变量和多变量 Cox 比例风险回归模型用于检查与 PTLD 相关的临床特征。
在分析队列中,有 19309 名 LTR,我们发现有 454 例 PTLD。PTLD 的 1 年累积发生率为 1.1%(95%CI=1.0%-1.3%),10 年累积发生率为 4.1%(95%CI=3.6%-4.6%)。PTLD 病例中,47.4%发生在肺移植后 1 年内。在多变量模型中,PTLD 的独立危险因素包括年龄、EB 病毒血清状态、限制性肺疾病和诱导治疗。在移植时年龄在 45 至 62 岁之间的患者中,PTLD 的风险随着年龄的增加而增加,而年龄<45 岁或>62 岁的患者则相反。最后,接受 HLA 类型 A1 和 A24 的供体器官与 PTLD 风险增加相关,而受者 HLA 类型 DR11 与 PTLD 风险降低相关。
我们的研究表明,PTLD 是成人 LTR 中相对罕见的并发症。我们确定了与 PTLD 风险增加相关的临床特征。